Publications by authors named "Naoko Totsuka"
Article Synopsis
- The N-MOmentum study evaluated the efficacy of inebilizumab, an anti-CD19 B cell-depleting antibody, in reducing attacks and worsening disability in NMOSD patients, including a specific focus on Asian participants.
- Subgroup analyses revealed that inebilizumab significantly lowered the risk of NMOSD attacks in the Asian group compared to placebo, with an attack-free rate of 82.1% versus 37.5% over 28 weeks.
- Overall, both Asian and non-Asian participants experienced similar NMOSD attack rates, suggesting that inebilizumab is effective across different populations despite some baseline differences.
Aim: To evaluate the efficacy, safety, and tolerability of apararenone 10 mg/day in patients with nonalcoholic steatohepatitis (NASH).
Methods: In this multicenter, randomized, double-blind, placebo-controlled phase II study, patients received apararenone 10 mg or placebo once daily for 72 weeks. The primary efficacy end-point was percent change in serum alanine aminotransferase (ALT) from baseline to 24 weeks after randomization.
Background: We investigated the efficacy and safety of apararenone (MT-3995), a non-steroidal compound with mineralocorticoid receptor agonist activity, in patients with stage 2 diabetic nephropathy (DN).
Methods: The study had two parts: a dose-response, parallel-group, randomized, double-blind, placebo-controlled, multicenter, phase 2, 24-week study and an open-label, uncontrolled, 28-week extension study. Primary and secondary endpoints were the 24-week percent change from baseline in urine albumin to creatine ratio (UACR) and 24- and 52-week UACR remission rates.